Company intelligence / Profile preview

Beijing Konruns Pharmaceutical Co., Ltd.

Ownership: Private
Employees: ~447
Development stage: Commercial

Overview

The company has approved products including Suling (haemocoagulase) and GuShuKang for osteoporosis. Multiple candidates are in clinical trials, including KC1036 (Phase 2 for solid tumors), Canlitinib (Phase 3 for esophageal cancer), and several products for chronic pelvic pain syndrome in Phase 3.

Therapeutic areas: Men's HealthHematologyEndocrinologyOncology
Modalities: Small molecule drugsHerbal medicineChemical drugs
Industry: Biotech

Drug pipeline

11 assets

jincaopian

10 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Beijing Konruns Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Konruns Pharmaceutical Co., Ltd..

Explore the full profile